Lantheus Holdings, Inc. sold $246K of CATX

Perspective Therapeutics (CATX) reported Q1 EPS of -$0.27, missing estimates by $0.03, with revenue of $20K, below the $74.68K consensus. The stock is down 72.4% over 3 months and 61.46% over 12 months. InvestingPro rates its financial health as weak.

Perspective Therapeutics, Inc. (CATX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Perspective Therapeutics Provides Recent Business Highlights and Reports 3Q 2026 Results • Updated interim data from the Phase 1/2a bamzireotide navoxetan (VMT-α-NET) presentations continue to support an emerging therapeutic window and potential to achieve a best-in-class profile

Perspective Therapeutics, Inc. (CATX) filed an SEC Form 8-K — Other Events. Perspective Therapeutics Presents Promising [212Pb]Lapemelanotide Zapixetar (VMT01) Monotherapy Data from a Phase 1/2a Study in Heavily Pretreated Advanced Melanoma Patients at SITC 2026 • Meaningful antitumor activity observed at the 3.0 mCi monotherapy dose with 75% disease con

Perspective Therapeutics (CATX) reported interim Phase 1/2a data for VMT01, showing 2 partial responses in 8 patients at the 3.0 mCi dose, with a 75% disease control rate. No dose-limiting toxicities or treatment-related serious adverse events were reported across 20 patients. The company continues dose optimization for future development.

Perspective Therapeutics (CATX) reported interim Phase 1/2a trial results for its melanoma treatment, lapemelanotide. Two of eight patients at the 3.0 mCi dose showed tumor shrinkage, with one response lasting ~40 weeks. No serious adverse events were reported. The company plans to continue dose optimization and development.

Perspective Therapeutics reported positive Phase 1/2a trial data for bamzireotide, showing 75% 18-month progression-free survival in GEP-NET patients. The company targets an end-of-Phase 2 meeting in 1Q 2027. No serious adverse events were reported.